Abstract
Idarubicin 12 mg/m2 has been recommended as a standard induction therapy for acute myeloid leukemia (AML). It is unknown whether a higher dose of idarubicin can improve the remission rate. This phase 2 prospective single-arm study enrolled 45 adults with newly diagnosed AML between September 2019 and May 2021 (NCT 04,069,208). Induction therapy included administration of idarubicin 14 mg/m2 for 3 days and cytarabine 100 mg/m2 every 12 h subcutaneously for 7 days. The primary endpoint was the composite complete response rate (complete response (CR) plus complete response with incomplete blood count recovery (CRi)). The median age was 45 years (range 14–60 years). Forty (88.9%) patients had CR or CRi, including 39 patients with CR and 1 patient with CRi after one course of induction therapy. The median times to recovery of absolute neutrophil and platelet counts were 21 days. Only 1 patient died of intracranial hemorrhage during induction therapy. After a median follow-up of 14 months (range 3.5–24 months), the estimated 18-month overall survival and disease-free survival (DFS) were 66.9% and 57.5%, respectively. In conclusion, idarubicin 14 mg/m2 plus cytarabine was a safe and efficient intensive regimen for younger and fit patients with newly diagnosed AML.
Similar content being viewed by others
References
Rai KR, Holland JF, Glidewell OJ et al (1981) Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 58:1203–1212
Berman E, Heller G, Santorsa J et al (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77:1666–1674
Vogler WR, Velez-Garcia E, Weiner RS et al (1992) A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol 10:1103–1111
Löwenberg B, Ossenkoppele GJ, van Putten W et al (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361:1235–1248
Fernandez HF, Sun Z, Yao X et al (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361:1249–1259
Lee JH, Joo YD, Kim H et al (2011) A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 118:3832–3841
Mandelli F, Vignetti M, Suciu S et al (2009) Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 27:5397–5403
Pautas C, Merabet F, Thomas X et al (2010) Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 28:808–814
Lee JH, Kim H, Joo YD et al (2017) Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia. J Clin Oncol 35:2754–2763
Burnett AK, Russell NH, Hills RK et al (2013) Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the Medical Research Council AML15 trial. J Clin Oncol 31:3360–3368
Holowiecki J, Grosicki S, Giebel S et al (2012) Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 30:2441–2448
Short NJ, Zhou S, Fu C et al (2020) Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol 6(12):1890–9
Cao XX, Cai H, Mao YY et al (2018) Next-generation sequencing-based genetic landscape and its clinical implications for Chinese acute myeloid leukemia patients. Cancer Cell Int 18:215
Döhner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424–447
Ohtake S, Miyawaki S, Fujita H et al (2011) Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 117:2358–2365
Jin J, Wang JX, Chen FF et al (2013) Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol 14:599–608
Wei H, Wang Y, Gale RP et al (2020) Randomized trial of intermediate-dose cytarabine in induction and consolidation therapy in adults with acute myeloid leukemia. Clin Cancer Res 26:3154–3161
DiNardo CD, Lachowiez CA, Takahashi K et al (2021) Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol 39:2768–2778
Acknowledgements
The authors thank the patients and their families.
Funding
This work was supported by the institutional research funding provided by the Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences (Grant No. 2019-RC-HL-001 to CXX) and the Beijing Natural Science Foundation (Grant No. 7202160 to CXX).
Author information
Authors and Affiliations
Contributions
Cao XX, Li J, and Zhou DB contributed to study conception and design; Mao YY contributed to patient follow-up; Mao YY and Cao XX contributed to data analysis and interpretation; Mao YY, Cai HC, Shen KN, Chang L, Zhang L, Zhang Y, Feng J, Wang W, Yang C, Zhu TN, Duan MH, Cao XX, and Li J contributed to patient enrollment; Mao YY and Cao XX wrote the paper; and all authors revised the paper and approved the submitted version.
Corresponding authors
Ethics declarations
Ethical approval
The study was approved by each site’s Institutional Ethics Committee and was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments.
Informed consent
Informed consent was obtained from all patients included in the study.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mao, Yy., Cai, Hc., Shen, Kn. et al. Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study. Ann Hematol 101, 831–836 (2022). https://doi.org/10.1007/s00277-022-04764-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-022-04764-4